Managing Director and Senior Biotechnology Analyst
Reni Benjamin, Ph.D., is a Managing Director and Senior Biotechnology Analyst. His expertise and company coverage consist of small-cap companies in the oncology and stem cell sectors. Dr. Benjamin has been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine and has been cited in a variety of sources including The Wall Street Journal, Business Week, Financial Times, Dow Jones Newswire, and Smart Money. He has also made appearances on Bloomberg television/radio and CNBC.
Prior to joining Rodman, Dr. Benjamin was an associate analyst in Needham and Company’s biotechnology equity research department. Prior to that, he earned his doctorate in Biochemistry by discovering and characterizing a novel gene implicated in germ cell development. His expertise includes biochemistry, functional genomics, gene therapy and molecular biology. Dr. Benjamin has presented at various regional and international conferences and published in peer-reviewed journals. Dr. Benjamin received his Ph.D. from the University of Alabama at Birmingham and his Bachelors of Science degree in Biology from Allegheny College.
